Quarterly report pursuant to Section 13 or 15(d)

Inventory

v3.2.0.727
Inventory
6 Months Ended
Jun. 30, 2015
Inventory Disclosure [Abstract]  
Inventory
Inventory

All components of inventory are valued at the lower of cost (first-in, first-out) or market. We adjust inventory to market value when the net realizable value is lower than the carrying cost of the inventory. Market value is determined based on estimated sales activity and margins.

The components of inventory as of June 30, 2015 and December 31, 2014, net of reserves of $465,000 and $539,000, respectively, are as follows:
 
June 30, 2015
 
December 31,
2014
 
(unaudited)
 
 
Materials
$
510,000

 
$

Work-in-process
284,453

 
1,034,476

Finished goods
865,349

 
436,936

Reserves
(464,693
)
 
(539,027
)
Total
$
1,195,109

 
$
932,385



During the six-month period ended June 30, 2015, we capitalized $791,000 of inventory costs associated with our Lymphoseek product. The Company capitalized no such costs during the same period in 2014. During the six-month period ended June 30, 2015, we wrote off $120,000 of materials related to production issues. During the six-month periods ended June 30, 2015 and 2014, we wrote off $123,000 and $45,000, respectively, of previously capitalized Lymphoseek inventory due to the consumption of the Lymphoseek material for product testing and development purposes.

We estimate a reserve for obsolete inventory based on management’s judgment of probable future commercial use, which is based on an analysis of current inventory levels, estimated future sales and production rates, and estimated shelf lives.